We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Methylphenidate Versus Placebo on State Anxiety in Children With Attention Deficit Hyperactivity Disorder.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01798459
Recruitment Status : Unknown
Verified March 2015 by Maya Kritchman Lupo, Shalvata Mental Health Center.
Recruitment status was:  Recruiting
First Posted : February 25, 2013
Last Update Posted : March 23, 2015
Sponsor:
Information provided by (Responsible Party):
Maya Kritchman Lupo, Shalvata Mental Health Center

Brief Summary:

The purpose of the study is to explore the effect of methylphenidate on state anxiety in children with attention deficit hyperactivity disorder.

Patient population: 30 children diagnosed with attention deficit hyperactivity disorder. The subjects will be of all racial, ethnical and gender categories, ranging from 8 to 18 years of age.

Structure: the study is a randomized double blind crossover study. The subjects will complete a continuous performance test, the cambridge neuropsychological test automated Battery, before and after given methylphenidate or placebo on the first day of the study. On the second day of the study, the subjects will receive either methylphenidate or placebo based on what was given on the first day of the study and they will complete the same task.


Condition or disease Intervention/treatment
Attention Deficit Hyperactivity Disorder Drug: Methylphenidate

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: A Double Blind Randomized Crossover Study of the Effect of Methylphenidate Versus Placebo on State Anxiety in Children With Attention Deficit Hyperactivity Disorder.
Study Start Date : February 2013
Estimated Primary Completion Date : October 2015
Estimated Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Methylphenidate
Methylphenidate 0.3 mg/kg per os is given before performing a continuous performance test.
Drug: Methylphenidate
Placebo Comparator: Placebo
Placebo is given before performing a continuous performance test.



Primary Outcome Measures :
  1. State anxiety [ Time Frame: 1 year ]
    State anxiety will be measured by the Spielberger's state anxiety inventory


Secondary Outcome Measures :
  1. Cognitive function [ Time Frame: 1 year ]
    Cognitive function will be measured by the cambridge neuropsychological test automated battery

  2. Patient's perspective [ Time Frame: 1 year ]
    Patient's perspective will be measured by questionnaires assessing treatment adherence issues and patient's view regarding the use of placebo.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   8 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Attention deficit and hyperactivity disorder
  • Children aged 8-18 years

Exclusion Criteria:

  • Pervasive developmental disorder
  • Schizophrenia
  • Bipolar disorder
  • Current depressive episode
  • Current Anxiety disorder
  • Drug use during the past 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01798459


Contacts
Contact: Maya Kritchman-Lupo, MD 972-9-7478644 maiakr@clalit.org.il; mayakri@gmail.com
Contact: Yuval Bloch, MD 972-9-7478510 yuvalbl@clalit.org.il

Locations
Israel
Shalvata Recruiting
Hod-hasharon, Israel
Contact: Maya Kritchman-Lupo, MD    972-9-7478644    maiakr@clalit.org.il; mayakri@gmail.com   
Sponsors and Collaborators
Shalvata Mental Health Center
Investigators
Principal Investigator: Maya Kritchman Lupo, MD Shalvata Mental Health Center

Responsible Party: Maya Kritchman Lupo, Resident, Shalvata Mental Health Center
ClinicalTrials.gov Identifier: NCT01798459     History of Changes
Other Study ID Numbers: 0009-12-SHA
First Posted: February 25, 2013    Key Record Dates
Last Update Posted: March 23, 2015
Last Verified: March 2015

Keywords provided by Maya Kritchman Lupo, Shalvata Mental Health Center:
Attention Deficit Hyperactivity Disorder
Methylphenidate
Placebo
State anxiety

Additional relevant MeSH terms:
Disease
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Nervous System Diseases
Hyperkinesis
Pathologic Processes
Dyskinesias
Neurologic Manifestations
Signs and Symptoms
Methylphenidate
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents